CYTK
Q4 2026 EPS Estimate
$-1.52
Nov 4, 2026 · Reports after close
Revenue Estimate
$40M
FY2029E EPS$0.82
FY2030E EPS$4.17

Analyst Sentiment

Wall St. Consensus
Buy
26 analysts·High coverage
74
Score
25 Buy (96%)1 Hold (4%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2596%
Hold
14%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$84.00
+8.4%
Consensus
$112.00
+44.6%
Bull
$140.00
+80.7%
12-Month Target Range26 analysts
$84.00$112.00$140.00
Current $77.47Consensus
Current Price
$77.47
Upside to Consensus
$34.53

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+246.25%
EPS
FY2028
Rev+124.25%
EPS
FY2029
Rev+72.61%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$114M$393M$882M$1.52B$2.32B
Low$93M$321M$698M$1.19B$1.81B
High$192M$499M$1.19B$2.11B$3.21B
EBITDA Avg$-114M$-393M$-882M$-1.52B$-2.32B
Low$-192M$-499M$-1.19B$-2.11B$-3.21B
High$-93M$-321M$-698M$-1.19B$-1.81B
EBIT Avg$-114M$-393M$-882M$-1.52B$-2.32B
Low$-192M$-499M$-1.19B$-2.11B$-3.21B
High$-93M$-321M$-698M$-1.19B$-1.81B
Net Income Avg$-774M$-658M$-333M$98M$501M
Low$-841M$-697M$-504M$70M$359M
High$-501M$-354M$13M$147M$752M
EPS Avg$-6.32$-4.67$-2.02$0.82$4.17
Low$-7.00$-5.80$-4.19$0.59$2.99
High$-4.17$-2.95$0.11$1.23$6.26
Analysts (Rev / EPS)16 / 1516 / 1516 / 1414 / 714 / 11
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$28M$45M$56M$81M$110M$148M$54M$59M
Low$19M$26M$36M$52M$70M$95M$35M$37M
High$54M$66M$85M$123M$167M$225M$82M$89M
EBITDA Avg$-28M$-45M$-56M$-81M$-110M$-148M$-54M$-59M
Low$-54M$-66M$-85M$-123M$-167M$-225M$-82M$-89M
High$-19M$-26M$-36M$-52M$-70M$-95M$-35M$-37M
EBIT Avg$-28M$-45M$-56M$-81M$-110M$-148M$-54M$-59M
Low$-54M$-66M$-85M$-123M$-167M$-225M$-82M$-89M
High$-19M$-26M$-36M$-52M$-70M$-95M$-35M$-37M
Net Income Avg$-206M$-196M$-189M$-189M$-175M$-155M$-180M$-149M
Low$-227M$-246M$-316M$-315M$-292M$-258M$-300M$-248M
High$-189M$-142M$-100M$-100M$-93M$-82M$-95M$-79M
EPS Avg$-1.56$-1.48$-1.43$-1.43$-1.32$-1.17$-1.36$-1.12
Low$-1.72$-1.86$-2.39$-2.39$-2.21$-1.95$-2.27$-1.88
High$-1.43$-1.08$-0.76$-0.76$-0.70$-0.62$-0.72$-0.60
Analysts (Rev / EPS)12 / 1118 / 169 / 89 / 713 / 79 / 1216 / 910 / 8

Earnings Surprises

Recent Analyst Actions

Aug 13, 2026Barclays
Cytokinetics price target raised to $110 from $95 at Barclays
Target:$110.00
+45.4%from $75.64
Aug 10, 2026Truist Financial
Cytokinetics price target raised to $112 from $106 at Truist
Target:$112.00
+46.5%from $76.44
Aug 7, 2026Needham
Cytokinetics price target raised to $112 from $102 at Needham
Target:$112.00
+46.7%from $76.32
Aug 7, 2026RBC Capital
Cytokinetics price target lowered to $112 from $117 at RBC Capital
Target:$112.00
+44.3%from $77.59
Jul 7, 2026RBC Capital
Cytokinetics price target lowered to $117 from $119 at RBC Capital
Target:$117.00
+36.7%from $85.57
Jun 29, 2026UBS
Cytokinetics upgraded to Buy from Neutral at UBS
Target:$115.00
+39.9%from $82.19
Jun 24, 2026Mizuho Securities
Cytokinetics price target raised to $118 from $100 at Mizuho
Target:$118.00
+47.5%from $80.01
Jun 17, 2026RBC Capital
RBC Capital on Cytokinetics (CYTK): 'The stock is significantly undervalued despite today's move'
Target:$119.00
+58.2%from $75.21
May 11, 2026H.C. Wainwright
Cytokinetics price target raised to $140 from $136 at H.C. Wainwright
Target:$140.00
+82.0%from $76.91
May 6, 2026Morgan Stanley
Cytokinetics price target raised to $103 from $90 at Morgan Stanley
Target:$103.00
+39.5%from $73.82
May 6, 2026UBS
Cytokinetics price target raised to $119 from $101 at RBC Capital
Target:$119.00
+60.1%from $74.34
May 6, 2026Stifel Nicolaus
Cytokinetics price target raised to $108 from $98 at Stifel
Target:$108.00
+40.1%from $77.09
May 5, 2026Truist Financial
Cytokinetics price target raised to $106 from $92 at Truist
Target:$106.00
+38.4%from $76.59
Apr 10, 2026Wells Fargo
Cytokinetics initiated with an Overweight at Wells Fargo
Target:$95.00
+46.9%from $64.66
Mar 10, 2026Robert W. Baird
Leerink Partners Reiterates Outperform Rating on Cytokinetics (CYTK) following conference
Target:$84.00
+32.2%from $63.55
Mar 6, 2026UBS
Cytokinetics (CYTK) PT Raised to $69 at UBS Amid Improved nHCM Outlook
Target:$69.00
+13.9%from $60.59
Feb 20, 2026RBC Capital
Cytokinetics price target raised to $101 from $95 at RBC Capital
Target:$101.00
+48.2%from $68.13
Feb 3, 2026Truist Financial
Cytokinetics price target raised to $92 from $84 at Truist
Target:$92.00
+38.4%from $66.47
Jan 9, 2026Jefferies
Cytokinetics (CYTK) PT Raised to $90 at Jefferies
Target:$90.00
+42.3%from $63.24
Jan 8, 2026Morgan Stanley
Cytokinetics price target raised to $90 from $71 at Morgan Stanley
Target:$90.00
+37.9%from $65.25
Dec 22, 2025Truist Financial
Cytokinetics price target raised to $84 from $70 at Truist
Target:$84.00
+24.8%from $67.33
Dec 22, 2025Morgan Stanley
Cytokinetics price target raised to $71 from $65 at Morgan Stanley
Target:$71.00
+5.4%from $67.39
Dec 22, 2025Leerink Partners
Cytokinetics price target raised to $83 from $73 at Leerink
Target:$83.00
+21.2%from $68.45
Dec 22, 2025RBC Capital
Cytokinetics price target raised to $95 from $87 at RBC Capital
Target:$95.00
+51.5%from $62.72
Dec 22, 2025Needham
Cytokinetics (CYTK) PT Raised to $84 at Needham
Target:$84.00
+21.3%from $69.25
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.